Vitro Biopharma appoints Thomas Ohrt as CFO; former CFO Nathan Haas to consult

Vitro Biopharma, Inc.

Nathan Haas resigned as CFO effective Jan 18, 2024; entered into Settlement and Consulting Agreements.
Haas to receive $175k unpaid bonus upon qualified financing or direct listing; 2023 bonus by April 1, 2024.
Haas will serve as strategy consultant for four months at $15,000/month.
Thomas Ohrt appointed CFO, salary $250k/year, eligible for $125k target performance bonus.
Ohrt served as controller since Jan 2021; 35 years of financial leadership experience.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nathan Haas

Chief Financial Officer

Vitro Biopharma, Inc.

Effective: 2024-01-18
Successor: Thomas W. Ohrt
Filed: January 23, 2024, 6:59 PM ET

Pursuant to the Settlement Agreement, the parties confirmed Mr. Haas’s resignation as Chief Financial Officer, effective January 18, 2024.

Appointed

Thomas W. Ohrt

Chief Financial Officer

Vitro Biopharma, Inc.

Effective: 2024-01-22
Filed: January 23, 2024, 6:59 PM ET

On January 22, 2024, Thomas W. Ohrt was appointed the Company’s Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nathan Haas resigned as Chief Financial Officer at Vitro Biopharma, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Pursuant to the Settlement Agreement, the parties confirmed Mr. Haas’s resignation as Chief Financial Officer, effective January 18, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas W. Ohrt was appointed as Chief Financial Officer at Vitro Biopharma, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On January 22, 2024, Thomas W. Ohrt was appointed the Company’s Chief Financial Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001493152-24-003346

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.